Nagai Akio, Miyazaki Miyono, Morita Teiichi, Furubo Shinichi, Kizawa Kazuo, Fukumoto Hiroyuki, Sanzen Takahiro, Hayakawa Hiroyoshi, Kawamura Yasuhito
Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan.
J Toxicol Sci. 2002 Aug;27(3):219-28. doi: 10.2131/jts.27.219.
The articular toxicity of garenoxacin (formerly T-3811 or BMS-284756) was experimentally examined utilizing juvenile beagle dogs. Garenoxacin and two other reference quinolones were administered at intravenous dosages of 30 and 60 mg/kg. Each group consisted of 3 male dogs (Experiment I). Oral dosages of 50 mg/kg of 3 compounds were also given daily to male only and female only groups (Experiment II) over a period of 7 days. We evaluated the articular toxicity of garenoxacin compared to ciprofloxacin and norfloxacin. In Experiment I, no articular toxicity was detected in the 30 mg/kg garenoxacin group. One animal from the 60 mg/kg garenoxacin group developed detectable histopathological lesions in the articular cartilages of the shoulder, elbow and knee joints. In the 30 mg/kg ciprofloxacin group and the 30 and 60 mg/kg norfloxacin groups, histopathological articular cartilage lesions of the shoulder, elbow, carpus, hip, knee and tarsus joints were observed in all of the dogs. The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively. In Experiment II, the degree of histopathological change was most significant in the ciprofloxacin group, followed by the norfloxacin group, and with comparatively the least changes in the garenoxacin group. The AUC0-->infinity values, obtained after the 6th day of antimicrobial administration, were 202 and 173 micrograms.hr/mL for male and female dogs, respectively, from the 50 mg/kg garenoxacin group. The AUC0-->infinity values for the garenoxacin group after the 6th daily administration were 7.8 to 17.0 times greater for male dogs and 3.8 to 13.2 times greater for female dogs than those obtained from the ciprofloxacin and norfloxacin groups. The concentrations of garenoxacin in the synovia, articular cartilage and the synovialis 4 hr following the last garenoxacin administration were 2.0 to 6.5 times higher for male dogs and 1.5 to 3.3 times higher for female dogs than the antimicrobial levels measured in the ciprofloxacin and norfloxacin groups. As discussed above, although the garenoxacin concentrations in plasma and joint tissue were higher than those for ciprofloxacin and norfloxacin, however, the articular toxicity of garenoxacin was much less than that of the other two antimicrobials.
利用幼年比格犬对加替沙星(原T-3811或BMS-284756)的关节毒性进行了实验研究。加替沙星及另外两种喹诺酮类对照药物以30和60mg/kg的静脉给药剂量给药。每组由3只雄性犬组成(实验I)。还分别对雄性组和雌性组每日口服50mg/kg的这3种化合物,持续7天(实验II)。我们评估了加替沙星与环丙沙星和诺氟沙星相比的关节毒性。在实验I中,30mg/kg加替沙星组未检测到关节毒性。60mg/kg加替沙星组的1只动物在肩关节、肘关节和膝关节的关节软骨中出现了可检测到的组织病理学损伤。在30mg/kg环丙沙星组以及30和60mg/kg诺氟沙星组中,所有犬均观察到肩关节、肘关节、腕关节、髋关节、膝关节和跗关节的组织病理学关节软骨损伤。首次给药后,30mg/kg加替沙星组、环丙沙星组和诺氟沙星组的血浆浓度-时间曲线下面积(AUC0→∞)值分别为164、68.1和65.7μg·hr/mL。在实验II中,组织病理学变化程度在环丙沙星组最为显著,其次是诺氟沙星组,加替沙星组变化相对最小。抗菌药物给药第6天后,50mg/kg加替沙星组雄性和雌性犬的AUC0→∞值分别为202和173μg·hr/mL。加替沙星组每日给药第6天后的AUC0→∞值,雄性犬比环丙沙星组和诺氟沙星组高7.8至17.0倍,雌性犬高3.8至13.2倍。最后一次给予加替沙星4小时后,雄性犬滑液、关节软骨和滑膜中加替沙星的浓度比环丙沙星组和诺氟沙星组测得的抗菌药物水平高2.0至6.5倍,雌性犬高1.5至3.3倍。如上所述,虽然加替沙星在血浆和关节组织中的浓度高于环丙沙星和诺氟沙星,但加替沙星的关节毒性远低于其他两种抗菌药物。